Aside from ibrutinib, people with M-CLL, devoid of TP53 aberrations and in good shape enough to tolerate FCR therapy, may still be great candidates for your latter, With all the reward remaining that this cure can be accomplished in 6 months while ibrutinib must be taken indefinitely. This option would be significantly worthwhile for non-compliant